BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10843452)

  • 41. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
    Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
    Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study comparing various noninvasive methods of detecting bladder cancer in urine.
    Saad A; Hanbury DC; McNicholas TA; Boustead GB; Morgan S; Woodman AC
    BJU Int; 2002 Mar; 89(4):369-73. PubMed ID: 11872026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Second resection in patients with Ta-T1 bladder tumors].
    Rodríguez-Rubio Cortadellas FI; Garrido Insua S; Rivas Aguayo D; Hens Pérez A; Bachiller Burgos J; Beltrán Aguilar V; Varo Solís C; Sánchez Bernal C; Juárez Soto A; González Moreno D
    Actas Urol Esp; 2001 Sep; 25(8):553-8. PubMed ID: 11692797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Noninvasive studies may have potential to replace cystoscopy in non-muscle invasive bladder cancer follow-up.
    Lee J; Heo JE; Kang SK; Lee KS; Han H; Jang WS; Choi YD
    Sci Rep; 2022 Dec; 12(1):21677. PubMed ID: 36522359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
    Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
    Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?
    Schips L; Augustin H; Zigeuner RE; Gallé G; Habermann H; Trummer H; Pummer K; Hubmer G
    Urology; 2002 Feb; 59(2):220-3. PubMed ID: 11834389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
    Miyanaga N; Akaza H; Tsukamoto S; Shimazui T; Ohtani M; Ishikawa S; Noguchi R; Manabe F; Nishijima Y; Kikuchi K; Sato K; Hayashi H; Kondo F; Shiraiwa H; Aoyama O
    Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of regular biopsy in the first cystoscopic follow-up and other predictors on the recurrence of superficial bladder tumors.
    Chang YH; Chuang CK; Pang ST; Wu CT; Chuang KL; Liao SK
    Chang Gung Med J; 2010; 33(2):174-87. PubMed ID: 20438670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnosis of bladder cancer using telomerase activity in voided urine.
    Cheng CW; Chueh SC; Chern HD
    J Formos Med Assoc; 2000 Dec; 99(12):920-5. PubMed ID: 11155745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer.
    Nakashima M; Matsui Y; Kobayashi T; Saito R; Hatahira S; Kawakami K; Nakamura E; Nishiyama H; Ogawa O
    Cancer Biomark; 2015; 15(4):357-64. PubMed ID: 26406865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
    Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
    BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A randomized study of prophylactic intravesical instillation of pirarubicin (THP) prior to transurethral resection of superficial bladder cancer].
    Hashimura T; Shirahase T; Inoue T; Yamasaki T; Terada N; Ogura K; Arai Y; Hida S; Ueda T
    Hinyokika Kiyo; 2005 Jul; 51(7):439-42. PubMed ID: 16119805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era.
    Takaoka E; Matsui Y; Inoue T; Miyazaki J; Nakashima M; Kimura T; Oikawa T; Kawai K; Yoshimura K; Habuchi T; Ogawa O; Nishiyama H
    Jpn J Clin Oncol; 2013 Apr; 43(4):404-9. PubMed ID: 23444116
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
    Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
    BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The criteria of patient selection for repeat transurethral resection of non-muscle invasive bladder cancer].
    Rolevich AI
    Urologiia; 2016 Apr; (2):71-76. PubMed ID: 28247665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can tumor recurrence be reduced with plasma-kinetic vaporization of the area around the tumor in nonmuscle invasive bladder cancer?
    Yılmaz Y; Kahya MC; Dilek FH; Köse O; Özcan S; Can E; Akın Y; Ergani B; Dindar AS
    Investig Clin Urol; 2018 Jul; 59(4):223-231. PubMed ID: 29984336
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
    Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
    Urologiia; 2000; (3):22-4. PubMed ID: 11186703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.